Verona, Italy-based technology company Techorizon, announced the launch of FeRMI, an electronic application to advance the conduct of clinical trial feasibility studies.
Verona, Italy-based technology company Techorizon, announced the launch of FeRMI, an electronic application to advance the conduct of clinical trial feasibility studies. Feasibility studies have been largely been paper or email based and are typically not integrated with other databases.
FeRMI creates an entirely integrated, electronic approach to the conduct of feasibility studies and promotes faster, more effective study planning. Each step of the process is managed electronically, with data collection from sites completed via highly customizable online surveys which include real time error checks. The investigator database module speeds selection of potential sites and tracks previous contacts and historical study performance. A real-time reporting module allows users to track trends emerging from the feasibility study whilst in progress, and ultimately to make better decisions about site selection.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.